← Back to Search

Procedure

Surgical Tissue Flap for Glioblastoma

N/A
Recruiting
Led By John Boockvar, MD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is investigating a surgical technique to improve outcomes for people with newly diagnosed brain tumor.

Who is the study for?
This trial is for adults over 18 with a confirmed diagnosis of Grade IV glioblastoma multiforme (GBM) who are candidates for significant tumor resection and have not started chemotherapy or radiation. They must be in good enough health to expect to live at least six more months, able to undergo MRI scans, and meet specific blood test criteria. Women of childbearing age must test negative for pregnancy and agree to birth control; men must also agree to use contraception.Check my eligibility
What is being tested?
The study is testing the safety and effectiveness of using a patient's own tissue flap—either temporoparietal fascial (TPF) or pericranial—to bypass the blood-brain barrier after surgical removal of GBM tumors. The goal is to see if this technique can improve survival without disease progression and overall lifespan in patients.See study design
What are the potential side effects?
Potential side effects may include complications from surgery such as infection, bleeding, reaction to anesthesia, pain at the graft site, swelling, or issues related to wound healing. Since it's a surgical procedure rather than drug therapy, traditional medication side effects are not applicable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (PFS)
Secondary outcome measures
Overall Survival (OS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Surgical tissue autograft: TPF flap/pericranial flapExperimental Treatment1 Intervention
Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
460 Previous Clinical Trials
471,011 Total Patients Enrolled
John Boockvar, MDPrincipal InvestigatorFeinstein Institute for Medical Research/Lenox Hill Hospital
13 Previous Clinical Trials
793 Total Patients Enrolled

Media Library

Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05954858 — N/A
Brain Tumor Research Study Groups: Surgical tissue autograft: TPF flap/pericranial flap
Brain Tumor Clinical Trial 2023: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap Highlights & Side Effects. Trial Name: NCT05954858 — N/A
Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05954858 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment of this experiment?

"Affirmative. Clinicaltrials.gov shows that this medical experiment, which was first posted on June 29th 2023, is currently recruiting patients. 32 participants need to be recruited from a single centre."

Answered by AI

Is this research initiative taking in new participants?

"Confirming the information accessible on clinicaltrials.gov, this trial is actively looking for participants after being originally posted on June 29th 2023 and updated most recently on July 13th of the same year."

Answered by AI
~19 spots leftby Jun 2025